血清单胺类神经递质及其代谢产物在重度抑郁症及抑郁共病焦虑障碍诊断中的应用

被引:48
作者
和昱辰 [1 ]
张波 [1 ]
瞿玮 [2 ]
宁洁 [2 ]
全弘宇 [2 ]
夏宇 [1 ]
姚远 [1 ]
韩梅 [1 ]
机构
[1] 第三军医大学西南医院:全军检验医学中心
[2] 第三军医大学西南医院:临床心理科
关键词
抑郁共病焦虑障碍; 抑郁症; 单胺类神经递质; 代谢产物;
D O I
10.16016/j.1000-5404.2014.08.026
中图分类号
R749.4 [情感性精神病];
学科分类号
摘要
目的观察血清单胺类神经递质及其代谢产物在抑郁症及抑郁共病焦虑障碍中水平的变化,并探讨其相关性。方法采用高效液相色谱法测定26例抑郁共病焦虑障碍、19例重度抑郁症评定:24项汉密尔顿抑郁量表总分>24和23例正常人血清的单胺类神经递质代谢产物血清肾上腺素(E)、去甲肾上腺素(NE)、五羟色胺(5-HT)以及二羟基苯乙酸(DOPAC)、高香草酸(HVA)、5-羟基吲哚乙酸(5-HIAA)的浓度,并比较两组上述单胺类神经递质及其代谢产物浓度的变化、比值和相关系数的差异。结果抑郁症组患者血清NE和E的浓度分别为(1.95±1.08)、(2.55±0.96)ng/L,共病组为(4.51±3.4)、(4.06±2.26)ng/L,对照组为(4.71±1.93)、(3.89±2.44)ng/L,3组两两之间相比均具有显著差异(P<0.05)。共病组血清5-HIAA、HAV的浓度为(0.9±1.5)、(1.58±1.48)ng/L,其浓度与对照组[分别为(0.17±0.08)、(0.76±0.39)ng/L]相比具有显著差异(P<0.05)。抑郁症组DOPAC与NE、5-HT与5-HIAA、HVA与5-HIAA的有明显的相关性(P<0.05);同时,抑郁症组与对照组相比,HVA/NE、DOPAC/NE、5-HIAA/NE、5-HT/5-HIAA、DOPAC/HVA比值存在显著差异(P<0.05),共病组在HVA/NE、5-HT/5-HIAA及DOPAC/HVA比值有显著差异(P<0.05)。抑郁症组与共病组各比值间均无显著差异(P>0.05)。结论血清单胺类神经递质及其代谢产物可反映大脑单胺类神经递质的平衡状态,其水平变化可作为抑郁症诊断生物标志的一个重要参考指标。
引用
收藏
页码:806 / 810
页数:5
相关论文
共 10 条
  • [1] 焦虑和抑郁障碍共病的临床现象学及心理社会因素和生物学研究(英文)
    袁勇贵
    张心保
    吴爱勤
    李箕君
    张宁
    张石宁
    [J]. 中国临床康复, 2005, (04) : 231 - 235
  • [2] Effects of the serotonin transporter polymorphism and history of major depression on overgeneral autobiographical memory
    Sumner, Jennifer A.
    Vrshek-Schallhorn, Suzanne
    Mineka, Susan
    Zinbarg, Richard E.
    Craske, Michelle G.
    Redei, Eva E.
    Wolitzky-Taylor, Kate
    Adam, Emma K.
    [J]. COGNITION & EMOTION, 2014, 28 (05) : 947 - 958
  • [3] Are there meaningful biomarkers of treatment response for depression?[J] . Barbara Breitenstein,Sandra Scheuer,Florian Holsboer.Drug Discovery Today . 2014
  • [4] Comorbidity and its relevance on general hospital based mortality in major depressive disorder: A naturalistic 12-year follow-up in general hospital admissions[J] . Dieter Schoepf,Hardeep Uppal,Rahul Potluri,Suresh Chandran,Reinhard Heun.Journal of Psychiatric Research . 2014
  • [5] The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs[J] . Ga?l Quesseveur,Alain M. Gardier,Bruno P. Guiard.Current Drug Targets . 2013 (11)
  • [6] Monoamine neurocircuitry in depression and strategies for new treatments[J] . Michel Hamon,Pierre Blier.Progress in Neuropsychopharmacology & Biological Psychiatry . 2013
  • [7] Functional topography of serotonergic systems supports the Deakin/Graeff hypothesis of anxiety and affective disorders
    Paul, Evan D.
    Lowry, Christopher A.
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2013, 27 (12) : 1090 - 1106
  • [8] Clinical utility of screening for clinical depression and bipolar disorder
    Mitchell, Alex J.
    [J]. CURRENT OPINION IN PSYCHIATRY, 2012, 25 (01) : 24 - 31
  • [9] An overview of the genetics of psychotic mood disorders[J] . Ming T. Tsuang,Levi Taylor,Stephen V. Faraone.Journal of Psychiatric Research . 2003 (1)
  • [10] Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression .2 Devane C Lindsay,Chiao Evelyn,Franklin Meg,Kruep Eric J. The American journal of managed care . 2005